216 related articles for article (PubMed ID: 28295628)
1. Pathophysiological aspects of red blood cells in end-stage renal disease patients resistant to recombinant human erythropoietin therapy.
Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Papageorgiou EG; Voulgaridou AI; Kokkalis AC; Antonelou MH; Papassideri IS
Eur J Haematol; 2017 Jun; 98(6):590-600. PubMed ID: 28295628
[TBL] [Abstract][Full Text] [Related]
2. Comparison of magnesium and zinc levels in blood in end stage renal disease patients treated by hemodialysis or peritoneal dialysis.
Pietrzak I; Bladek K; Bulikowski W
Magnes Res; 2002 Dec; 15(3-4):229-36. PubMed ID: 12635877
[TBL] [Abstract][Full Text] [Related]
3. Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy.
Costa E; Rocha S; Rocha-Pereira P; Castro E; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Blood Purif; 2008; 26(3):267-73. PubMed ID: 18417959
[TBL] [Abstract][Full Text] [Related]
4. Erythropoiesis and erythrocyte age distribution in hemodialysis patients undergoing erythropoietin therapy.
Hampl H; Riedel E; Scigalla P; Stabell U; Wendel G
Blood Purif; 1990; 8(3):117-25. PubMed ID: 2244989
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of hemodiafiltration versus conventional hemodialysis on erythrocyte performance.
Georgatzakou HT; Tzounakas VL; Kriebardis AG; Velentzas AD; Kokkalis AC; Antonelou MH; Papassideri IS
Can J Physiol Pharmacol; 2018 Mar; 96(3):249-257. PubMed ID: 28854342
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress-associated shape transformation and membrane proteome remodeling in erythrocytes of end stage renal disease patients on hemodialysis.
Antonelou MH; Kriebardis AG; Velentzas AD; Kokkalis AC; Georgakopoulou SC; Papassideri IS
J Proteomics; 2011 Oct; 74(11):2441-52. PubMed ID: 21515423
[TBL] [Abstract][Full Text] [Related]
7. Recipient's effects on stored red blood cell performance: the case of uremic plasma.
Georgatzakou HT; Tzounakas VL; Velentzas AD; Papassideri IS; Kokkalis AC; Stamoulis KE; Kriebardis AG; Antonelou MH
Transfusion; 2019 Jun; 59(6):1900-1906. PubMed ID: 30888086
[TBL] [Abstract][Full Text] [Related]
8. The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure.
Túri S; Németh I; Varga I; Bodrogi T; Matkovics B
Pediatr Nephrol; 1992 Nov; 6(6):536-41. PubMed ID: 1482641
[TBL] [Abstract][Full Text] [Related]
9. Treatment of renal anaemia with recombinant human erythropoietin results in decreased red cell uptake of 45Ca.
Linde T; Ronquist G; Sandhagen B; Wikström B; Frithz G; Pettersson L; Danielson BG
Nephron; 1994; 68(4):419-26. PubMed ID: 7870225
[TBL] [Abstract][Full Text] [Related]
10. Red blood cell calcium homeostasis in patients with end-stage renal disease.
Gafter U; Malachi T; Barak H; Djaldetti M; Levi J
J Lab Clin Med; 1989 Sep; 114(3):222-31. PubMed ID: 2527934
[TBL] [Abstract][Full Text] [Related]
11. Correlation between serum carnitine levels and erythrocyte osmotic fragility in hemodialysis patients.
Matsumura M; Hatakeyama S; Koni I; Mabuchi H; Muramoto H
Nephron; 1996; 72(4):574-8. PubMed ID: 8730424
[TBL] [Abstract][Full Text] [Related]
12. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
[TBL] [Abstract][Full Text] [Related]
13. Nucleotide and glutathione status in erythrocytes of children undergoing chronic hemodialysis under erythropoietin treatment.
Sachs G; Siems W; Grune T; Schmidt G; Gerber G; Zoellner K
Biomed Biochim Acta; 1990; 49(2-3):S123-4. PubMed ID: 2386496
[TBL] [Abstract][Full Text] [Related]
14. Lipid peroxidation and vitamin E in red blood cells and plasma in hemodialysis patients under rhEPO treatment.
Nenov D; Paskalev D; Yankova T; Tchankova P
Artif Organs; 1995 May; 19(5):436-9. PubMed ID: 7625923
[TBL] [Abstract][Full Text] [Related]
15. Characterization of circulating erythrocytes from myelodysplastic patients treated with recombinant human erythropoietin.
Shapiro S; Gershon H; Rosenbaum H; Merchav S
Leukemia; 1993 Sep; 7(9):1328-33. PubMed ID: 8371583
[TBL] [Abstract][Full Text] [Related]
16. Red blood cell osmotic fragility in chronically hemodialyzed patients.
Wu SG; Jeng FR; Wei SY; Su CZ; Chung TC; Chang WJ; Chang HW
Nephron; 1998; 78(1):28-32. PubMed ID: 9453400
[TBL] [Abstract][Full Text] [Related]
17. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
[TBL] [Abstract][Full Text] [Related]
18. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
19. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment.
Zachée P; Ferrant A; Daelemans R; Coolen L; Goossens W; Lins RL; Couttenye M; De Broe ME; Boogaerts MA
Nephron; 1993; 65(2):288-93. PubMed ID: 8247195
[TBL] [Abstract][Full Text] [Related]
20. Nitric oxide synthetic pathway and cGMP levels are altered in red blood cells from end-stage renal disease patients.
Di Pietro N; Giardinelli A; Sirolli V; Riganti C; Di Tomo P; Gazzano E; Di Silvestre S; Panknin C; Cortese-Krott MM; Csonka C; Kelm M; Ferdinandy P; Bonomini M; Pandolfi A
Mol Cell Biochem; 2016 Jun; 417(1-2):155-67. PubMed ID: 27206740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
